Business Description
PAVmed Inc
NAICS : 334510
SIC : 3842
Share Class Description:
PAVMW: Warrants (29/01/2022)Total Employee Number:
41Description
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.38 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | -0.77 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.48 | |||||
Beneish M-Score | 41.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -61.8 | |||||
3-Year EBITDA Growth Rate | 80.9 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | 72.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.02 | |||||
Quick Ratio | 1.96 | |||||
Cash Ratio | 1.76 | |||||
Days Inventory | 326.4 | |||||
Days Sales Outstanding | 43.8 | |||||
Days Payable | 724.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -64.1 | |||||
Shareholder Yield % | 48.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -227.06 | |||||
Operating Margin % | -28036.47 | |||||
Net Margin % | -21914.12 | |||||
EBITDA Margin % | -25945.88 | |||||
ROE % | -47.26 | |||||
ROA % | -42.52 | |||||
ROIC % | -51.39 | |||||
3-Year ROIIC % | 2240.34 | |||||
ROC (Joel Greenblatt) % | -997.93 | |||||
ROCE % | -65.19 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 54.27 | |||||
PB Ratio | 0.85 | |||||
EV-to-EBIT | -1.55 | |||||
EV-to-EBITDA | -1.56 | |||||
EV-to-Revenue | 404.12 | |||||
EV-to-FCF | -5.46 | |||||
Earnings Yield (Greenblatt) % | -64.52 | |||||
FCF Yield % | -18.2 |
GF Value™
PAVmed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PAVmed Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 138 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 47 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 46 days | ||
| General meeting for 2026 | 2026-06-18 10:00 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-15 08:30 | -- | ||
| First quarter earnings results for 2026 | 2026-05-15 | -- | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 10:15 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 08:30 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | -- |
Show
Entries
Guru Commentaries on NAS:PAVMW
No articles.
Press Release
Articles on PAVmed Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers